Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | NNMT | P40261 | 3/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2310300 | 1.00 | MKNK1 (0.42) | MKNK1MKNK2SIRT3TDP1ADORA3 | |
| SCHEMBL2492969 | 0.82 | TSHR (0.48) | SIRT3ADORA3TSHRMC4RADRA1A | |
| SCHEMBL5518273 | 0.80 | KDM4E (0.36) | MKNK1MKNK2TSHRKDM4EPKM | |
| SCHEMBL29364216 | 0.78 | SMN1; SMN2 (0.39) | MKNK1MKNK2TSHRKDM4EPKM | |
| SCHEMBL287450 | 0.78 | KDM4E (0.47) | TSHRKDM4EPKMALDH1A1MAPT | |
| SCHEMBL23864829 | 0.78 | KDM4E (0.35) | MKNK1MKNK2TSHRKDM4EPKM | |
| SCHEMBL29526925 | 0.78 | KDM4E (0.47) | TSHRKDM4EPKMALDH1A1MAPT | |
| SCHEMBL13544700 | 0.78 | ADORA3 (0.41) | SIRT3TDP1ADORA3TSHRMC4R | |
| SCHEMBL335305 | 0.78 | SMN1; SMN2 (0.39) | MKNK1MKNK2TSHRKDM4EPKM | |
| SCHEMBL23032651 | 0.76 | KDM4E (0.34) | MKNK1MKNK2TSHRKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107422-A1 | 6-(PYRIDIN-4-YL)-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12459927-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-20240228501-A1 | IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| EP-4293023-A1 | IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022222963-A1 | IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | 长春金赛药业有限责任公司 | 2022-10-27 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | MKNK1 2518/4885MKNK2 2157/4885SIRT3 1243/4885 |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | MKNK1 1678/4885MKNK2 1205/4885SIRT3 88/4885 |
| US-20240228501-A1 | IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | KISS1R, CYP3A43, SLC6A11 | MKNK1 2023/4885MKNK2 2767/4885SIRT3 358/4885 |
| US-12459927-B2 | Plasma kallikrein inhibitors | KLKB1, SERPINE1, KLK5 | MKNK1 373/4885MKNK2 559/4885SIRT3 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.